Form 4: Vivo Opportunity, LLC Sells Shares of Soleno Therapeutics Inc (SLNO)
SEC Form 4
Vivo Opportunity, LLC, a 10% owner of Soleno Therapeutics Inc, reports selling a significant number of shares over three days in August 2024.
Summary
- Vivo Opportunity, LLC, along with Vivo Opportunity Fund Holdings, L.P., filed a Form 4 detailing the sale of Soleno Therapeutics Inc (SLNO) common stock.
- The transactions occurred over three days: August 27, 2024, August 28, 2024, and August 29, 2024.
- On August 27, 2024, 500,000 shares were sold at a weighted average price of $48.73, with prices ranging from $47.00 to $51.17.
- On August 28, 2024, 425,000 shares were sold at a weighted average price of $47.35, with prices ranging from $46.79 to $48.92.
- On August 29, 2024, 100,000 shares were sold at a weighted average price of $47.22, with prices ranging from $46.47 to $47.95.
- Following these transactions, Vivo Opportunity Fund Holdings, L.P. beneficially owns 6,291,851 shares of Soleno Therapeutics Inc.
- Vivo Opportunity, LLC disclaims beneficial ownership except to the extent of its pecuniary interest.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative due to the large sale of shares by a significant shareholder, which could indicate a lack of confidence or a strategic shift.
Negatives
- A significant shareholder, Vivo Opportunity, LLC, is reducing its stake in Soleno Therapeutics Inc.
Risks
- Continued selling pressure from Vivo Opportunity, LLC could negatively impact the stock price.
- The reason for the sale is not disclosed, which could create uncertainty among investors.
Industry Context
Form 4 filings are standard disclosures for significant shareholders and insiders, providing transparency into their trading activities. This sale could be part of a broader portfolio rebalancing strategy or reflect a change in the investor's outlook on the company.
Stakeholder Impact
- Shareholders may react negatively to the news of a large shareholder selling shares.
- The company may experience downward pressure on its stock price in the short term.
Key Dates
| Date | Description |
|---|---|
| 08/27/2024 | 500,000 shares of common stock sold at a weighted average price of $48.73. |
| 08/28/2024 | 425,000 shares of common stock sold at a weighted average price of $47.35. |
| 08/29/2024 | 100,000 shares of common stock sold at a weighted average price of $47.22. |
| 08/29/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.